Similar Search Results

Incorporation of Uncertainty in Health Economic Modelling Studies

O'Hagan, Anthony; McCabe, Christopher; Akehurst, Ron; … - In: PharmacoEconomics 23 (2005) 6, pp. 529-536

-simplified to the point of providing a bad example of modelling practice, which may mislead the readers of PharmacoEconomics. The …

Persistent link: https://www.econbiz.de/10004990337

Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients: Modelling Study from the Hospital Perspective in Germ...

Schadlich, Peter K.; Kentsch, Michael; Weber, Manfred; … - In: PharmacoEconomics 24 (2006) 6, pp. 571-591

were quantified using a modelling approach based on the decision-tree technique. Resource use during thromboprophylaxis …

Persistent link: https://www.econbiz.de/10004990355

New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses

Mapel, Douglas W.; Roberts, Melissa H. - In: PharmacoEconomics 30 (2012) 10, pp. 869-885

such as Markov modelling, and they have usually found that newer therapies have favourable cost effectiveness. However, new …, known as exacerbations, and approaches to modelling the cost benefit of exacerbation reduction; (iii) quality …; (v) the limitations of Markov modelling; and (vi) the problem of outliers. …

Persistent link: https://www.econbiz.de/10010569819

A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects

McKenna, Stephen P.; Doward, Lynda C. - In: PharmacoEconomics 16 (1999) 4, pp. 417-419

Persistent link: https://www.econbiz.de/10005243154

A Systematic Review to Assess the Policy-Making Relevance of Dementia Cost-of-Illness Studies in the US and Canada

Oremus, Mark; Aguilar, S. Carolina. - In: PharmacoEconomics 29 (2011) 2, pp. 141-156

A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content...

Persistent link: https://www.econbiz.de/10010614323

Management of Mild to Moderate Alzheimer Disease: Defining the Role of Rivastigmine

Plosker, Greg L.; Keating, Gillian M. - In: Disease Management and Health Outcomes 12 (2004) 1, pp. 55-72

Alzheimer disease is a common, progressive neurodegenerative disorder of the elderly, affecting approximately 3% of individuals 65-74 years of age, and up to half of those aged =85 years. Along with progressive loss of memory and cognitive function, other symptoms include depression and...

Persistent link: https://www.econbiz.de/10005448926

A Review of Quality of Life in Alzheimer's Disease: Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects

Salek, Sam S.; Walker, Melvyn D.; Bayer, Anthony J. - In: PharmacoEconomics 15 (1999) 6, pp. 641-644

Persistent link: https://www.econbiz.de/10005449019

Donepezil: Pharmacoeconomic Implications of Therapy

Foster, Rachel H.; Plosker, Greg L. - In: PharmacoEconomics 16 (1999) 1, pp. 99-114

_ Donepezil is a specific acetylcholinesterase inhibitor that can improve symptoms in patients with mild-to-moderate Alzheimer's disease; cognitive function is maintained above baseline levels for up to 1 year and normal decline of cognitive function is slowed. The ability of the patient to...

Persistent link: https://www.econbiz.de/10005449093

A Review of Quality of Life in Alzheimer's Disease: Part 1: Issues in Assessing Disease Impact

Walker, Melvyn D.; Salek, Sam S.; Bayer, Antony J. - In: PharmacoEconomics 14 (1998) 5, pp. 499-530

There are numerous methods available for assessing patients with Alzheimer's disease (AD) or other forms of dementia. Quality-of-life (QOL) assessment is unique among these methods, because the QOL concept itself includes a subjective component that is fundamental to its measurement. It could be...

Persistent link: https://www.econbiz.de/10005449174

Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer's Disease

Green, Colin; Picot, Joanna; Loveman, Emma; Takeda, Andrea - In: PharmacoEconomics 23 (2005) 12, pp. 1271-1282

Objective: To estimate the cost effectiveness (from the UK NHS and personal social services perspective) of the cholinesterase inhibitors donepezil, rivastigmine and galantamine compared with usual care in the treatment of mild to moderately severe Alzheimer's disease. Patients had a mean age of...

Persistent link: https://www.econbiz.de/10005449271